#NWSCONF2023
Learn about MeMed's host
immune response technology at
MeMed is transforming patient care by listening to the immune system and turning host response signals into clinical action.
MeMed's AWARD Winning Technology!
AACC Disruptive Technology Award Finalist – MeMed COVID-19 Severity was selected as one of three finalists! Come hear more about this revolutionary technology!
Lecture Series
Dr. Eran Eden
Co-founder and CEO of MeMed
MeMed: A Leader in Host Response Technology
What would your antibiotic stewardship program look like if you had a 15-minute test that could differentiate between a bacterial and viral infection? MeMed BV® is the first rapid and accurate (blinded and external validation) host-response technology for distinguishing between bacterial and viral infections in under 15 minutes, and it is changing the paradigm in infectious disease patient management.
AACC Poster Presentations
Dr. Niv Samuel Mastboim
Director of Product Innovation at MeMed
COVID-19 Severity™: Leveraging the immune response to improve outbreak management: Derivation of a rapidly measurable host-protein signature for stratifying severity of COVID-19 patients
Click to Download
Dr. Einav Simon
Director of R&D Clinical Science at MeMed
MeMed Key: Validating the analytical reproducibility of a new chemiluminescence-based point-of-need platform for multiplex protein measurements across pg/ml to µg/ml range: Key® and BV
Click to Download
Observer: A rapidly measurable host assay comprising TRAIL, IP-10, and CRP has the potential to reduce antibiotic overuse without increasing underuse in adults with suspected lower respiratory tract infection.
Dr. Tanya Gottlieb
VP Scientific Affairs at MeMed
Click to Download
About MeMed
At MeMed, a leader in host response technologies, we decode the body's complex signals into simple insights that improve people's lives. By leveraging our expertise in host-response profiling and machine-learning algorithms, we are creating a portfolio of tests that address tough clinical dilemmas.
Importantly, with the support of public and private partnerships, we have developed a point-of-need, rapid measurement platform called MeMed Key to ensure timely availability of these novel tests during the clinician’s decision-making workflow.
